Home › Filings & Releases › July 2026

Filings & Releases — July 2026

499 documents from 207 companies (198 releases) · updated Nov 7, 2026

Company

All filings (+180)

Friday, July 3121

Thursday, July 3049

ZNTLZentalis PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
XFORX4 PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
XENEXenon PharmaceuticalsReleaseXenon to Report Q2 2026 Financial Results on August 6, 2026
WVEWave Life SciencesReleaseWave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
WVEWave Life Sciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → WVE pipeline
WVEWave Life Sciences10-QQuarterly report
VSTMVerastemSCHEDULE 13G/A13G amendment
VORVor BiopharmaSCHEDULE 13GPassive >5% holder (13G)
VKTXViking TherapeuticsS-3ASRAutomatic shelf registration
VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
UNCYUnicycive TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
TYRATyra BiosciencesSCHEDULE 13GPassive >5% holder (13G)
TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
STROSutro BiopharmaSCHEDULE 13GPassive >5% holder (13G)
SRPTSarepta TherapeuticsSCHEDULE 13G/A13G amendment
SPRBSpruce BiosciencesSCHEDULE 13GPassive >5% holder (13G)
SLDBSolid BiosciencesSCHEDULE 13GPassive >5% holder (13G)
SGMTSagimet BiosciencesSCHEDULE 13GPassive >5% holder (13G)
SABSSAB BiotherapeuticsReleaseSAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
REPLReplimune GroupReleaseReplimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced MelanomaBD extracted 1 program update from this document → REPL pipeline
REPLReplimune Group8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
RAREUltragenyx PharmaceuticalSCHEDULE 13G/A13G amendment
RAREUltragenyx PharmaceuticalReleasePowered by Purpose: Celebrating our Emerging Talent
ORICOric PharmaceuticalsS-8Employee plan registration
ORICOric Pharmaceuticals8-KCurrent report: officer / director change
OCGNOcugenDEFA14AProxy soliciting material
OCGNOcugenDEF 14AProxy statement
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
NRSNNeuroSense TherapeuticsF-3/AF-3/A
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin BiotechS-1/ARegistration statement (amended)
KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
IRONDisc Medicine8-KCurrent report: results of operations · EX-99.1
IRONDisc Medicine10-QQuarterly report
INMBInmune BioReleaseINmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platformvia aggregator
IBRXImmunityBio8-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → IBRX pipeline
EYPTEyePointReleaseEyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
EYPTEyePoint8-KCurrent report: other events · EX-99.1
EVMNEvommuneReleaseEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
EVMNEvommune8-KCurrent report: Reg FD disclosure · EX-99.1
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
DBVTDBV TechnologiesReleaseDBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
CTNMContineum Therapeutics8-KCurrent report: results of operations · EX-99.1
CTNMContineum Therapeutics10-QQuarterly report
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
CLRBCellectar BiosciencesReleaseCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 LEARN MORE
CINGCingulateReleaseCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
CBIOCrescent BiopharmaReleaseCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → CBIO pipeline
CBIOCrescent BiopharmaPOS AMPost-effective amendment
CBIOCrescent Biopharma8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → CBIO pipeline
CBIOCrescent Biopharma424B3Prospectus (resale / update)
CBIOCrescent Biopharma10-QQuarterly report
CAPRCapricor TherapeuticsReleaseCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
CAPRCapricor Therapeutics8-KCurrent report: other events · EX-99
BCYCBicycle Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
BCYCBicycle Therapeutics10-QQuarterly report
ATHEAlterity TherapeuticsReleaseQ4 FY26 Quarterly Cash Flow Report & Corporate Update
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATAIAtai BeckleyPREM14APreliminary merger proxy
ANNXAnnexonReleaseAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
ANNXAnnexon8-KCurrent report: material agreement, debt / obligation, other events · EX-99.1
ANABAnaptysBio8-KCurrent report: Reg FD disclosure
ALDXAldeyra Therapeutics8-KCurrent report: material agreement
AGIOAgios Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
AGIOAgios Pharmaceuticals10-QQuarterly report

Wednesday, July 2941

Tuesday, July 2833

VSTMVerastemReleaseVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancervia aggregator
TVTXTravere TherapeuticsReleaseTravere Therapeutics to Report Second Quarter 2026 Financial Results
TTRXTurn TherapeuticsReleaseTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED JULY 28, 2026BD extracted 1 program update from this document → TTRX pipeline
SRPTSarepta TherapeuticsS-8Employee plan registration
RLMDRelmada TherapeuticsReleaseRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
RLMDRelmada Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE ISSUED ON JULY 28, 2026
RAREUltragenyx PharmaceuticalReleaseUltragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
QTTBQ32 BioEFFECTRegistration effective
QTTBQ32 Bio424B3Prospectus (resale / update)
PMVPPMV PharmaceuticalsSCHEDULE 13G/A13G amendment
PMNProMIS NeurosciencesReleaseProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
PMNProMIS Neurosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → PMN pipeline
OCGNOcugenReleaseOcugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
NKTRNektar TherapeuticsReleaseNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
LEGNLegend BiotechReleaseLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JULY 28, 2026
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KYMRKymera TherapeuticsReleaseWATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
IVVDInvivydSCHEDULE 13GPassive >5% holder (13G)
IMRXImmuneeringSCHEDULE 13GPassive >5% holder (13G)
HRMYHarmony BiosciencesSCHEDULE 13G/A13G amendment
GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationBD extracted 1 program update from this document → GRCE pipeline
GRCEGrace TherapeuticsDEFA14AProxy soliciting material
GRCEGrace TherapeuticsDEF 14AProxy statement
GRCEGrace Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
FBRXForte BiosciencesSCHEDULE 13GPassive >5% holder (13G)
FBRXForte BiosciencesSC TO-CSC TO-C
EYPTEyePointSCHEDULE 13G/A13G amendment
ETONEton PharmaceuticalsSCHEDULE 13G/A13G amendment
ENTXEntera Bio8-KCurrent report: material agreement, unregistered sale of equity, officer / director change
DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
DYNDyne TherapeuticsReleaseDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
CGENCompugenCORRESPCORRESP
CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
CATXPerspective TherapeuticsReleasePerspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
BCAXBicara TherapeuticsReleaseBicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BCAXBicara Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ARVNArvinasReleaseArvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
ALTAltimmuneReleaseAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
ALTAltimmune8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → ALT pipeline
ACHVAchieve Life SciencesSCHEDULE 13G/A13G amendment

Monday, July 2730

Friday, July 2412

VIRVir BiotechnologyReleaseVir Biotechnology Announces Chief Financial Officer Transition
VIRVir Biotechnology8-KCurrent report: officer / director change
REPLReplimune GroupS-3/AShelf registration (amended)
PRQRProQR TherapeuticsSCHEDULE 13G/A13G amendment
OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDBD extracted 1 program update from this document → OTLK pipeline
OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
OTLKOutlook Therapeutics8-KCurrent report: officer / director change
ONCYOncolytics Biotech8-KCurrent report: listing notice
NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
NAMSNewAmsterdam Pharma8-KCurrent report: other events · EX-99.1
IVVDInvivyd8-KCurrent report: listing notice
GOSSGossamer BioSCHEDULE 13D/A13D amendment
APVOAptevo TherapeuticsS-8Employee plan registration

Thursday, July 2318

WVEWave Life SciencesReleaseWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
VSTMVerastemReleaseVerastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
SMMTSummit TherapeuticsReleaseSummit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
SMMTSummit Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
SMMTSummit Therapeutics8-KCurrent report: material agreementBD extracted 1 program update from this document → SMMT pipeline
SMMTSummit Therapeutics424B5Prospectus supplement (offering)
SMMTSummit Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → SMMT pipeline
NVCTNuvectis PharmaReleaseCorrection: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitorsvia aggregator
NVCTNuvectis PharmaReleaseCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitorsvia aggregator
LGVNLongeveronReleaseDeborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
IXHLIncannex HealthcareReleaseIncannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JULY 23, 2026
IMVTImmunovantReleaseImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026via aggregator
DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CINGCingulate8-KCurrent report: officer / director change
CABACabaletta BioSCHEDULE 13G/A13G amendment
BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) CongresBD extracted 1 program update from this document → BEAM pipeline
ARTVArtiva BiotherapeuticsSCHEDULE 13D/A13D amendment
ARDXArdelyxReleaseArdelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Wednesday, July 2225

VIRVir BiotechnologyReleaseVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JULY 22, 2026
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Announce Second Quarter 2026 Financial Results
SMMTSummit TherapeuticsReleaseIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
SMMTSummit TherapeuticsReleaseArcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBD extracted 1 program update from this document → SMMT pipeline
SMMTSummit Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → SMMT pipeline
RNACCartesian TherapeuticsSCHEDULE 13G/A13G amendment
RCUSArcus BiosciencesReleaseArcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Eval...
RCUSArcus BiosciencesReleaseArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboratio...BD extracted 1 program update from this document → RCUS pipeline
QUREuniQureReleaseuniQure to Announce Second Quarter 2026 Financial Results
NRXPNRX Pharmaceuticals8-KCurrent report: other events
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JULY 22, 2026
NAMSNewAmsterdam Pharma8-KCurrent report: officer / director change
LBRXLB Pharmaceuticals8-KCurrent report: other events · EX-99.1
LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
KROSKeros Therapeutics8-KCurrent report: officer / director change
KAPAKairos Pharma8-KCurrent report: material agreement, other events · EX-99.1
INSMInsmedSCHEDULE 13G/A13G amendment
IMVTImmunovantDEFA14AProxy soliciting material
IMVTImmunovantDEF 14AProxy statement
IMVTImmunovantARSAnnual report to shareholders
GUTSFractyl HealthReleaseFractyl Health to Participate in Upcoming Investor Eventsvia aggregator
GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomBD extracted 1 program update from this document → GLSI pipeline
EXELExelixisReleaseExelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
DYNDyne Therapeutics8-KCurrent report: material agreement, other events · EX-99.1
DYNDyne Therapeutics424B5Prospectus supplement (offering)
CUECue BiopharmaDForm D (exempt offering)
CRVSCorvus Pharmaceuticals8-KCurrent report: officer / director change
ARTVArtiva Biotherapeutics8-KCurrent report: other events

Tuesday, July 2126

VORVor BiopharmaSCHEDULE 13D/A13D amendment
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
SGMTSagimet Biosciences8-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → SGMT pipeline
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
RNTXRein Therapeutics8-KCurrent report: shareholder vote
RCUSArcus BiosciencesReleaseArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financi...
PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 21, 2026, TITLED "POLYPID ANNOUNCES
PHIOPhio Pharmaceuticals8-KCurrent report: officer / director change, other events · EX-99.1 EXHIBIT 99.1
OTLKOutlook TherapeuticsEFFECTRegistration effective
OTLKOutlook Therapeutics424B3Prospectus (resale / update)
NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo
NKTRNektar TherapeuticsReleaseNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisBD extracted 1 program update from this document → NKTR pipeline
MESOMesoblast6-KForeign issuer report · EX-99.1
KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026BD extracted 1 program update from this document → KTTA pipeline
IMRXImmuneeringReleasePublication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
HELPHelus PharmaReleaseHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
HELPHelus Pharma6-KForeign issuer report · EX-99.1
DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
DYNDyne Therapeutics424B5Prospectus supplement (offering)
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JULY 21, 2026BD extracted 1 program update from this document → DRTS pipeline
CRNXCrinetics PharmaceuticalsPREM14APreliminary merger proxy
CLDXCelldex TherapeuticsReleaseCelldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo NodularisBD extracted 2 program updates from this document → CLDX pipeline
ATHEAlterity TherapeuticsReleaseAlterity to Participate in the BTIG Biotechnology Conference
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ACRVAcrivon TherapeuticsReleaseAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Monday, July 209

SCYXScynexisSCHEDULE 13G/A13G amendment
QUREuniQureSCHEDULE 13G/A13G amendment
QTTBQ32 BioSCHEDULE 13D/A13D amendment
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
OMEROmeros8-KCurrent report: other events
OCGNOcugenPRE 14APRE 14A
IMMXImmix Biopharma8-KCurrent report: other events
GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Provides Clinical Updates on FLAMINGO-01BD extracted 1 program update from this document → GLSI pipeline
FDMT4D Molecular Therapeutics8-KCurrent report: other events
DYNDyne TherapeuticsReleaseDyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
DYNDyne Therapeutics8-KCurrent report: other events
DTILPrecision BiosciencesSCHEDULE 13GPassive >5% holder (13G)
CBIOCrescent BiopharmaSCHEDULE 13D/A13D amendment
CATXPerspective TherapeuticsSCHEDULE 13GPassive >5% holder (13G)

Saturday, July 181

FDMT4D Molecular TherapeuticsRelease4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationBD extracted 1 program update from this document → FDMT pipeline

Friday, July 1710

XERSXeris Biopharma8-KCurrent report: unregistered sale of equity, other events
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
QTTBQ32 BioS-3Shelf registration
OTLKOutlook TherapeuticsS-3Shelf registration
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
KROSKeros TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
JBIOJade BiosciencesSCHEDULE 13GPassive >5% holder (13G)
IMTXImmaticsReleaseImmatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026BD extracted 3 program updates from this document → IMTX pipeline
EYPTEyePoint8-KCurrent report: material agreement
DBVTDBV TechnologiesReleaseDBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Salesvia aggregator
CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
CGENCompugenUPLOADUPLOAD
CATXPerspective TherapeuticsReleasePerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
ATAIAtai BeckleySCHEDULE 13D/A13D amendment
ACTUActuate Therapeutics8-KCurrent report: listing notice

Thursday, July 1633

VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in EuropeBD extracted 1 program update from this document → VNDA pipeline
QUREuniQureSCHEDULE 13GPassive >5% holder (13G)
QNRXQuoin PharmaceuticalsDEF 14AProxy statement
QNRXQuoin PharmaceuticalsARSAnnual report to shareholders
OTLKOutlook Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
LBRXLB PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
INSMInsmed8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
INBXInhibrx Biosciences8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
IMUXImmunicSCHEDULE 13G/A13G amendment
HRMYHarmony Biosciences8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
HELPHelus PharmaDForm D (exempt offering)
HELPHelus PharmaDForm D (exempt offering)
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01BD extracted 1 program update from this document → GLSI pipeline
GANXGain TherapeuticsReleaseGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateBD extracted 1 program update from this document → GANX pipeline
GANXGain Therapeutics8-KCurrent report: other events
FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
EWTXEdgewise Therapeutics8-K/ACurrent report (amended) · EX-99.1 EXHIBIT 99.1
EVMNEvommuneSCHEDULE 13GPassive >5% holder (13G)
ENTXEntera Bio8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
ELTXElicio TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
DBVTDBV TechnologiesReleaseDBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business UpdateBD extracted 1 program update from this document → DBVT pipeline
DBVTDBV TechnologiesReleaseDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBVTDBV Technologies8-KCurrent report: results of operations · EX-99.1
DBVTDBV Technologies10-QQuarterly report
CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from PsychotherapyBD extracted 1 program update from this document → CMPS pipeline
CMMBChemomab TherapeuticsSCHEDULE 13DActivist / >5% holder (13D)
CBIOCrescent BiopharmaReleaseCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BCTXBriaCell TherapeuticsReleaseBriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancervia aggregator
ATAIAtai BeckleyReleaseLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionscompany site may be offline after the acquisition; linked to the SEC copy · original
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai Beckley8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1

Wednesday, July 1525

VNDAVanda PharmaceuticalsReleaseNEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatmentvia aggregator
QTTBQ32 Bio8-KCurrent report: material agreement
QTTBQ32 Bio424B5Prospectus supplement (offering)
PYPDPolyPid6-KForeign issuer report · EX-99.1 AMENDED AND RESTATED 2012 SHARE OPTION PLAN
PRQRProQR TherapeuticsSCHEDULE 13G/A13G amendment
PRQRProQR TherapeuticsEFFECTRegistration effective
PRQRProQR Therapeutics424B5Prospectus supplement (offering)
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decisionvia aggregator
PCVXVaxcyte8-KCurrent report: officer / director change
MLTXMoonLake Immunotherapeutics8-KCurrent report: other events
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin BiotechDRSDRS
LEGNLegend Biotech6-KForeign issuer report
KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
GUTSFractyl HealthReleaseFractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuationvia aggregatorBD extracted 1 program update from this document → GUTS pipeline
GUTSFractyl Health8-KCurrent report: Reg FD disclosure, other events · EX-99.1
GOSSGossamer Bio8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
ERASErascaReleaseErasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED JULY 15, 2026
CLRBCellectar BiosciencesReleaseCellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers LEARN MOREBD extracted 1 program update from this document → CLRB pipeline
CLDXCelldex TherapeuticsReleaseCelldex Announces Planned Transition of Chief Financial Officer
CLDXCelldex Therapeutics8-KCurrent report: officer / director change
CINGCingulateS-8Employee plan registration
CBIOCrescent Biopharma8-KCurrent report: other events · EX-99.1
CBIOCrescent Biopharma424B5Prospectus supplement (offering)
AXSMAxsome Therapeutics8-KCurrent report: other events · EX-99.1
ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic SolBD extracted 1 program update from this document → ALLO pipeline
ALDXAldeyra Therapeutics8-KCurrent report: other events
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Tuesday, July 1422

SNDXSyndax Pharmaceuticals8-KCurrent report: other events · EX-99.1
SMMTSummit TherapeuticsReleaseSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
RNTXRein TherapeuticsSCHEDULE 13G/A13G amendment
RCKTRocket PharmaceuticalsS-8Employee plan registration
MESOMesoblast6-KForeign issuer report · EX-99.1
LGVNLongeveron8-KCurrent report: officer / director change
KURAKura OncologyReleaseKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026BD extracted 1 program update from this document → KURA pipeline
IMUXImmunic8-KCurrent report: Reg FD disclosure · EX-99.1
ERASErasca8-KCurrent report: other events · EX-99.1
ERASErasca424B5Prospectus supplement (offering)
DFTXDefinium TherapeuticsReleaseNew Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
DBVTDBV TechnologiesReleaseDBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026via aggregator
CRVOCervoMedReleaseCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
CRDLCardiol TherapeuticsReleaseCardiol Therapeutics’ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart AssociationBD extracted 1 program update from this document → CRDL pipeline
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED JULY 14, 2026
CINGCingulate8-KCurrent report: officer / director change, shareholder vote
CBIOCrescent BiopharmaReleaseCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
CBIOCrescent BiopharmaReleaseCrescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
CBIOCrescent Biopharma8-KCurrent report: results of operations
CBIOCrescent Biopharma424B5Prospectus supplement (offering)
CAPRCapricor Therapeutics8-KCurrent report: material agreement, debt / obligation
ANNXAnnexonReleaseAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026BD extracted 1 program update from this document → ANNX pipeline
ABSIAbsciReleaseAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Monday, July 1322

VYGRVoyager TherapeuticsReleaseVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026BD extracted 1 program update from this document → VYGR pipeline
VYGRVoyager Therapeutics8-KCurrent report: other events
SANASana BiotechnologyReleaseSana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell TransplantaBD extracted 1 program update from this document → SANA pipeline
REPLReplimune GroupPRE 14APRE 14A
QTTBQ32 BioEFFECTRegistration effective
QTTBQ32 Bio8-KCurrent report: other events · EX-99.1
QTTBQ32 Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1
QTTBQ32 Bio424B5Prospectus supplement (offering)
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
OCGNOcugenReleaseOcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
OCGNOcugen8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
LGVNLongeveronReleaseLongeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Pat
EYPTEyePointReleaseEyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
EWTXEdgewise Therapeutics8-KCurrent report: acquisition / disposition, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ERASErascaS-3ASRAutomatic shelf registration
ERASErascaReleaseErasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERASErascaReleaseErasca Announces Pricing of Upsized Public Offering of Common Stock
ERASErascaReleaseErasca Announces Proposed Public Offering of $500 Million of Common Stock
ERASErasca8-KCurrent report: other events
ERASErasca424B5Prospectus supplement (offering)
CUECue BiopharmaReleaseCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
CTNMContineum Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
CGTXCognition TherapeuticsReleaseCognition Therapeutics Participating in Fireside Chat at B. Riley Securities’ Mind, Muscle & Vision Summit
APGEApogee TherapeuticsDEFM14AMerger proxy

Friday, July 1011

Thursday, July 922

VERAVera TherapeuticsReleaseVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
VERAVera Therapeutics8-KCurrent report: officer / director change
TVTXTravere Therapeutics8-KCurrent report: officer / director change
NRIXNurix TherapeuticsReleaseNurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NRIXNurix Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → NRIX pipeline
NRIXNurix Therapeutics10-QQuarterly report
KYTXKyverna Therapeutics8-KCurrent report: material agreement
IPSCCentury TherapeuticsReleaseCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
INABIN8bioReleaseIN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed GlioblastomaBD extracted 1 program update from this document → INAB pipeline
HURATuHURA BiosciencesDEFA14AProxy soliciting material
HURATuHURA BiosciencesDEF 14AProxy statement
HURATuHURA BiosciencesARSAnnual report to shareholders
GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01BD extracted 1 program update from this document → GLSI pipeline
FBRXForte BiosciencesReleaseFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Periodcompany site may be offline after the acquisition; linked to the SEC copy · original
FBRXForte Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → FBRX pipeline
CUECue BiopharmaReleaseCue Biopharma Announces $50.0 Million Private Placement
CRVOCervoMedReleaseCervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
CRDLCardiol TherapeuticsReleaseCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED JULY 9, 2026
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1

Wednesday, July 811

Tuesday, July 718

WVEWave Life SciencesReleaseWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
VORVor BiopharmaReleaseVor Bio Appoints David Zaccardelli to Board of Directors
VORVor Biopharma8-KCurrent report: officer / director change
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
VERAVera TherapeuticsReleaseVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA NephropathyBD extracted 1 program update from this document → VERA pipeline
VERAVera Therapeutics8-KCurrent report: other events
TTRXTurn TherapeuticsReleaseTurn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED JULY 7. 2026BD extracted 1 program update from this document → TTRX pipeline
TARAProtara TherapeuticsSCHEDULE 13G/A13G amendment
SABSSAB Biotherapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
MGTXMeiraGTx8-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1
KYMRKymera TherapeuticsReleaseDr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026
HURATuHURA Biosciences8-KCurrent report: debt / obligation
CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
CMPSCOMPASS Pathways8-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → CMPS pipeline
CLYMClimb BioSCHEDULE 13D/A13D amendment
BCTXBriaCell TherapeuticsReleaseBriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™via aggregator
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Monday, July 621

TTRXTurn TherapeuticsReleaseTurn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic DermatitisBD extracted 1 program update from this document → TTRX pipeline
QTTBQ32 BioSCHEDULE 13G/A13G amendment
QNRXQuoin PharmaceuticalsPRE 14APRE 14A
PRQRProQR TherapeuticsF-3Shelf registration (foreign)
OMEROmeros8-KCurrent report: other events
MDNAFMedicenna TherapeuticsDForm D (exempt offering)
LGVNLongeveronReleaseLongeveron® Appoints Marie Washburn as Chief Financial Officer
LGVNLongeveron8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote · EX-99.1 PRESS RELEASE DATED JULY 6, 2026
IVVDInvivyd8-KCurrent report: other events · EX-99.1
IMUXImmunic8-KCurrent report: officer / director change
GLUEMonte Rosa TherapeuticsSCHEDULE 13D/A13D amendment
DBVTDBV TechnologiesReleaseHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFvia aggregator
CRVOCervoMedS-3Shelf registration
CRVOCervoMedReleaseCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026BD extracted 1 program update from this document → CRVO pipeline
CRNXCrinetics PharmaceuticalsReleaseVertex to Acquire Crinetics Pharmaceuticalscompany site may be offline after the acquisition; linked to the SEC copy · original
CRNXCrinetics PharmaceuticalsDEFA14AProxy soliciting material
CRNXCrinetics PharmaceuticalsDEFA14AProxy soliciting material
CRNXCrinetics Pharmaceuticals8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
BBOTBridgeBio Oncology TherapeuticsSCHEDULE 13D/A13D amendment
ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
ATAIAtai BeckleyReleaseAtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive DisorderBD extracted 1 program update from this document → ATAI pipelinecompany site may be offline after the acquisition
ADAGAdagene6-KForeign issuer report
ACHVAchieve Life Sciences8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
ABVXAbivaxSCHEDULE 13D/A13D amendment

Thursday, July 219

UNCYUnicycive Therapeutics8-KCurrent report: other events
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
TENXTenax Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → TENX pipeline
NGNENeurogene8-KCurrent report: material agreement, other events
NGNENeurogene424B5Prospectus supplement (offering)
NGENNervGen PharmaSUPPLSUPPL
NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
LENZLENZ Therapeutics8-KCurrent report: officer / director change
KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
ENTAEnanta Pharmaceuticals8-KCurrent report: material agreement
ENTAEnanta Pharmaceuticals424B5Prospectus supplement (offering)
ELTXElicio Therapeutics8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
ELTXElicio Therapeutics424B5Prospectus supplement (offering)
CINGCingulateReleaseCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CINGCingulate8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
ARDXArdelyx8-KCurrent report: debt / obligation
APGEApogee TherapeuticsPREM14APreliminary merger proxy
AGIOAgios PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
ADCTADC Therapeutics8-KCurrent report: officer / director change
ABVXAbivax6-KForeign issuer report
ABVXAbivax424B5Prospectus supplement (offering)

Wednesday, July 120

ZURAZura Bio8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
XFORX4 Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
SANASana BiotechnologyReleaseSana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026BD extracted 1 program update from this document → SANA pipeline
RCUSArcus BiosciencesReleaseNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in ...BD extracted 1 program update from this document → RCUS pipeline
ORKAOruka TherapeuticsSCHEDULE 13D/A13D amendment
OCGNOcugenReleaseOcugen to Participate in Upcoming July Industry Conferences
MESOMesoblast6-KForeign issuer report · EX-99.1
KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
JBIOJade Biosciences8-KCurrent report: material agreement
INMBInmune Bio8-KCurrent report: material agreement
GOSSGossamer BioSCHEDULE 13D/A13D amendment
GOSSGossamer BioReleaseGossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
GOSSGossamer Bio8-KCurrent report: Reg FD disclosure · EX-99.1
ERASErasca8-KCurrent report: shareholder vote
DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events
CUECue BiopharmaEFFECTRegistration effective
CMPXCompass Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
CLYMClimb Bio8-KCurrent report: officer / director change
CBIOCrescent BiopharmaS-3Shelf registration
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ABVXAbivaxFWPFree writing prospectus (offering terms)